Clinical trial / 2010
Formula supplementation with DHA at 0.32% or higher improved infant visual acuity at 12 months, with no extra benefit from higher doses.
Researchers conducted a double-masked randomized trial evaluating 343 healthy term infants assigned to infant formulas with 0% DHA (control), 0.32% DHA, 0.64% DHA, or 0.96% DHA (all supplemented formulas also included 0.64% arachidonic acid). Infants fed the control formula had significantly poorer visual evoked potential visual acuity at 12 months of age compared to those receiving any DHA-supplemented formula (P < 0.001). No significant differences in visual acuity were observed among the 3 amounts of DHA supplementation at either site or any age tested.
- Study type
- Double-masked randomized controlled trial
- Who was studied
- 343 healthy, term, formula-fed infants enrolled at 1-9 days of age (244 completed 12-month exam)
- What was measured
- Visual evoked potential visual acuity at 12 months of age
THE PAPER
The DIAMOND (DHA Intake And Measurement Of Neural Development) Study: a double-masked, randomized controlled clinical trial of the maturation of infant visual acuity as a function of the dietary level of docosahexaenoic acid.
Birch EE, Carlson SE, Hoffman DR, Fitzgerald-Gustafson KM, Fu VL, Drover JR, Castañeda YS, Minns L, Wheaton DK, Mundy D, Marunycz J, Diersen-Schade DA. Am J Clin Nutr, 2010.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.